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31. Abstract
Objective: The treatment of advanced head and neck squamous cell carcinoma
(HNSCC) with induction chemotherapy before radiation therapy has become more
acknowledged over the last few years. The aim of our study was to find out, if
histopathological parameters of the untreated primary tumor in HNSCC e.g. initial
primary tumor grade, proliferation index, glucose transporter protein 1 (GLUT-1)
expression could be possibly related to therapy response. Sequential 18F-FDG-
PET/CT imaging before and after induction chemotherapy and resulting 18F-FDG-
uptake was used as a surrogate for therapy response and compared to patient
outcome.
Materials and Methods: 21 patients with advanced HNSCC treated by induction
chemotherapy as first-line therapy were consecutively enrolled in this study. Defined
responders (standardized uptake value (SUV) decrease > 75%) and non-responders
(SUV decrease < 25%) were correlated to initial tumor grade (well, moderately,
poorly differentiated) and other histopathological parameters including mitotic index,
regression score and the expression of the GLUT-1 receptor for possible response
predictive factors. Further, patient outcome was evaluated especially regarding
survival.
Results: No significant correlation (p=0.472) could be found between response and
histological grading (moderately or poorly differentiated). There was no significant
difference between the SUV response and composition of chemotherapy (p=0.465),
overall cycles (p=0.407), T-stage (p=0.557) or location of primary tumor (p=0.054).
After a mean follow-up of 12 months, 6 patients were dead of disease, of which 5 had
been classified as partial or non-responders and only one as a complete responder
by 18F-FDG-PET/CT.
4Conclusion: Since metabolic response was not correlated to initial histological
parameters, response to chemotherapy can not be predicted by histopathological
parameters alone. However, 18F-FDG-PET/CT seems to be a useful imaging
protocol to monitor therapy response and may help to define therapy decision after
induction chemotherapy.
52. Introduction
Carcinomas of the head and neck region represent 6.5% of the overall cancer
incidents [1]. The majority of them (90%) are of squamous cell origin [1]. The
common risk factors for developing head and neck squamous cell carcinoma
(HNSCC) are the abuse of tobacco and alcoholic beverages. Men are more
frequently affected than women, but the proportion of female patients has risen
slightly due to the increased consumption of alcohol and tobacco among the latter
group [2, 3].
The survival rate for patients with HNSCC (approximately 55% after 5 years) is still
low even though various efforts have been undertaken to improve the outcome of
HNSCC [1].
The treatment plan for patients suffering from HNSCC is a very demanding task;
often discussed and planned on a multidisciplinary approach by a team of head and
neck surgeons, radio-oncologists, medical oncologists, radiologists, nuclear
physicians and pathologists.
Early stage disease is well treated by a single approach consisting of surgery or
radiotherapy alone, whereas advanced stage disease often requires a
multidisciplinary approach combining these modalities. Further, chemotherapy has
gained importance over the last years and concurrent chemo-radiotherapy is
standard of care, when a curative approach is chosen [1, 4, 5, 6].
Lately, the role of chemotherapy has even increased using the idea of an induction
chemotherapy (mostly consisting of docetaxel, cisplatin and 5-fluorouracil –
abbreviated DCF) which is applied in a neo-adjuvant setting before definitive therapy
[7, 8, 9].
The motivation for this kind of treatment is based on the general idea, that if patients
respond well to induction chemotherapy, systemic micrometastasis as well as the
primary tumor volume will be significantly reduced before definitive locoregional
therapy, possibly improving patient’s outcome. It is unclear and still under
investigation whether a complete response of the tumor to induction therapy should
lead to a reduction of the radiation doses and whether this has an impact on the
planning of the following radiation therapy [10].
6Positron emission tomography with 18F-fluoro-2-deoxy-D-glucose (18F-FDG-PET) in
combination with computed tomography (CT) plays an important role at initial staging
and re-staging after therapeutic interventions, since change in 18F-FDG-uptake has
been positively correlated to therapy response [11, 12]. In a recent publication by
Kikuchi et al. sequential 18F-FDG-PET/CT after induction chemotherapy has been
shown to be predictive of histopathological response in patients with HNSCC [13].
Histopathological response is considered the gold-standard for therapy assessment,
however observation of tumor changes by using imaging modalities such as CT or
magnetic imaging (MRI) has been used for evaluating therapy response after
induction chemotherapy and is well described previously [13, 14, 15, 16].
The aim of our study was to find out, if histopathological parameters of the untreated
primary tumor in HNSCC e.g. initial primary tumor grade, proliferation index, glucose
transporter protein 1 (GLUT-1) expression could be possibly related to therapy
response. If the success of therapy could be predicted by these rather simple
histological analyses, a personalized therapy could be established as well as harmful
therapies omitted. 18F-FDG-PET/CT imaging has demonstrated the potential to
determine non-invasively therapy response in several solid tumors including HNSCC
[12]. In this study, sequential 18F-FDG-PET/CT imaging before and after induction
chemo-therapy and resulting dynamics of 18F-FDG-uptake was used as a surrogate
for therapy response. 18F-FDG-uptake in 18F-FDG-PET/CT can be objectively
assessed by measurement by so called standard uptake values of 18F-FDG-avid
lesions including the primary tumor and its metastases. Responders were defined as
those having a standardized uptake value (SUV) decrease of greater than 75%
whereas non-responders were defined as those having a SUV decrease less than
25%. Patient outcome was also determined regarding the hard end-point of alive or
dead-of-disease. By this simplified approach a possible link to the success of
induction treatment could be made, even though not proved since only post-
therapeutic histological analysis of tumor tissue would be regarded as gold-standard.
73. Materials and Methods
3.1. Patients
In this retrospective analysis we selected patients from January 2007 to January
2010 suffering from advanced stage HNSCC and treated by induction chemotherapy
treatment as the first step before further curative local treatment. As second inclusion
criteria, all patients had to be initially staged and re-staged after induction
chemotherapy by 18F-FDG-PET/CT. In a second step, only patients who were not
pretreated, especially chemo-naïve were then selected for final analysis. Essentially,
all patients were first staged at the Department of Otorhinolaryngology, Head and
Neck Surgery, University Hospital Zurich, Switzerland. As an institutional policy 18F-
FDG-PET/CT was only performed in advanced disease to rule out second primaries
or distant metastases. Informed consent was waived according to local ethical
committee policy.
The clinical characteristics of the 21 patients are shown in table 1. An oversight in
table 2 shows for every patient the location and stage of the tumor, the performed
therapies, the follow-up in months and whether they were alive or were dead of
disease (DOD) at the end of the follow-up.
3.2. Induction chemotherapy
As for induction chemotherapy, standard treatment protocol consisted of docetaxel
(Taxotere®), a taxoid which leads to the polymerisation of the tubuli to stable
microtubuli and inhibits the depolymerisation thus leading to an interference during
the mitosis; cisplatin which shows a cytotoxic effect as a result of interfering with the
deoxyribonucleic acid (DNA) metabolism independent of the cell cycle; and 5-
fluorouracil (5-FU), a pyrimidine analogue which interferes with the synthesis of
nucleic acid. Docetaxel and cisplatin were given per infusion on day one of the
treatment cycle, each in a dosage of 75 mg/m². 5-fluorouracil was given as a
permanent infusion in a dosage of 750 mg/m² from day one to day five.
Patient related deviations from this treatment protocol were made when necessary
(e.g., reduced dosages, replacement of cisplatin with carboplatin in patients with
renal insufficiency).
8Cetuximab (Erbitux®), a monoclonal IgG1-antibody which blocks the epithelial growth
factor receptor (EGFR), was given in selected cases. This tyrosine kinase receptor
stimulates cell proliferation, therefore it inhibits apoptosis and plays an important role
in angiogenesis within the tumor. Cetuximab was given together with cisplatin or
carboplatin and 5-FU. The dosage consisted of 400 mg/m² for the first cycle and 250
mg/m² for all the following cycles. Cisplatin was given in the dosage of 100mg/m² on
day one; 5-FU as a permanent infusion in the dosage of 1000 mg/m² from day one to
day four.
The dosage of the drugs which were used was as follows (sometimes slightly
altered):
In the ‘DCF’ scheme one cycle consists of 75 mg/m² docetaxel and 75 mg/m²
cisplatin on day one and 750 mg/m² 5-fluorouracil from day one to five. The
cetuximab, 5-fluorouracil and carboplatin or cisplatin scheme consists of 400 mg/m²
cetuximab on day one in the first cycle and for the following cycles 250 mg/m²
cetuximab on day one, 100 mg/m² cisplatin on day one and 1000 mg/m² 5-fluoruracil
from day one to four.
The details of the drugs used and the number of cycles of the induction
chemotherapy are shown for each patient in table 3. This table also shows after how
many cycles the 18F-FDG-PET/CT re-staging was done. The time gap between the
last cycle before re-staging and the re-staging 18F-FDG-PET/CT was in most cases
only a few days; all except one have been done within a span of two weeks. In one
case the time gap was one and a half months due to health complications after the
induction chemotherapy.
3.3. Imaging protocol
To complete the tumor staging and to evaluate its response to induction
chemotherapy a 18F-FDG-PET/CT inline system (Discovery LS, RX or Discovery
STE, GE Health Systems, Milwaukee, WI) was used. These devices combine a PET
scanner with a multi-slice helical CT with a slice thickness of 2.5 mm, which enables
the computation of coregistered PET and CT images in the same session.
9Prior to scanning, patients had to fast for four hours at a minimum. Approximately
sixty minutes before the scan, patients were given the injection of a standard dose of
350 megabecquerel (MBq) of 18F-FDG. Oral CT contrast agent (Micropaque
Scanner, Guerbet AG, Aulnay-sous-bois, France) was applied a quarter of an hour
before the injection of the 18F-FDG. Before scanning, all patients were tested for a
normal glucose level (range 4.4 – 6.7 mmol/L). During their examination, patients
were in a supine position and for the period of the CT scan they were instructed to
hold their breath in the normal expiratory position. The acquisition of the PET
emission scan followed immediately after the completion of the CT scan. The
attenuation correction was acquired through the CT data and a standard iterative
algorithm (OSEM: ordered set expectation maximization) was used for reconstructing
the images for the 3D PET reconstruction. For viewing the acquired images a
software providing multiplanar reformatted images of 18F-FDG-PET alone, CT alone
and combined 18F-FDG-PET/CT with linked cursors was employed using an AW
workstation (AW 4.4, GE Health Systems, Waukesha, WI, USA).
3.4. Analysis of 18F-FDG-PET/CT images
For a semiquantitative analysis of 18F-FDG uptake within the tumor tissue we
measured the SUVmax over a freehand region of interest including the primary tumor
site and cervical lymph node metastasis. For the correction of the SUVmax we used
the lean body mass (LBM) of the patient, which was determined by a personal scale
(Tanita, model 2001; Tanita, Tokyo, Japan). This model was supplied with an
integrated foot-to-foot bioelectric impedance analyser. For the calculation of the LBM
data on gender we used weight, height and a measured impedance value for the
determination of the percentage of body fat. We determined the SUVmax by the
following equation: SUVmax(LBM)=(LBM – CFDG)/D; CFDG being the concentration of
18F-FDG in becquerels per milliliter, and D being the injected dose measured in
becquerels. LBM was measured in grams.
To correct for physiological 18F-FDG uptake in this analysis, we measured the SUV
of the bloodpool and substracted this value from the SUVmax of the tumor, in order to
determine the absolute tumor SUV (SUVabs).
In addition, the volume of the primary tumor was measured in cm³ by using a 42%
threshold of SUVmax. If cervical lymph node involvement was present, this volume
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was added.
Regarding tumor response assessment, the following three parameters were chosen:
 Non-responder: a change of the SUVabs of less than minus 25% of the initial
value (SUVabs from the pre-therapy 18F-FDG-PET/CT).
 Partial responder: a change of the SUVabs between minus 25% and minus
75% of the initial value.
 Complete responder: a change of the SUVabs of over minus 75% of the initial
value.
3.5. Histopathological examination
All patients underwent a cytological or histological verification of the primary tumor
and lymph node metastases before treatment. The cytological/histological
specimens, respectively, were examined for the mitotic index and the GLUT-1
expression of tumor tissue, as well as the regression score which represents the
proportion of the necrotic tumor cells within the tumor before treatment. To estimate
the proliferation rate of a tumor, an immunohistochemical staining with MIB-1 was
used, an antibody against Ki-67, which is a protein expressed in proliferating cells.
Cells in mitosis are marked with MIB-1.
Tumor tissue was further examined for glucose transporter protein 1 (GLUT-1)
expression, a transmembrane transport protein for both glucose and vitamin C, which
shows a correlation to the malignancy of the tumor and represents an indicator for
hypoxia within the tumor tissue [17, 18, 19].
Regarding GLUT-1 scoring, the following three parameters were chosen: score 0: 0%
- 25%, score 1: 25% - 50%, score 2: 50% - 75%, score 3: 75% - 100%.
Regarding the tumor regression score, we examined samples with hematoxylin and
eosin stain (HE stain) for vital and necrotic tumor cells, signs of surrounding
inflammation and fibrotic reorganisation.
The tumor regression score from 0 to 2 depends on the proportion of vital tumor cells
of the overall tumor tissue. The following three parameters were chosen: score 0: 0%
- 10%, score 1: 10% - 50%, score 2: 50% - 100%.
Of the 21 patients, 3 patients had a biopsy or cytology sample taken before the
initiation of induction chemotherapy which was not usable for our study. In 16 patients
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biopsy samples and in 2 patients cytology samples were available for analysis. From
all biopsy samples MIB score, GLUT-1 score and the tumor regression score were
determined. From the cytology samples, MIB and GLUT-1 score were available.
3.6. Statistical analysis
We assessed the correlation between the SUV response and respectively the
histological grading of the tumor, the induction chemotherapy scheme and the
number of cycles, the primary tumor site and the TNM staging of the HNSCC. For
statistical analysis, a Fisher exact test, especially eligible for small patient population,
was used to determine the level of significance. A p-value < 0.05 was regarded as
significant. All statistical analyses were performed using the SPSS 17 (SPSS Inc.
Chicago, Illinois).
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4. Results
4.1. Patients and tumor characteristics
From 2007 to 2010 251 patients underwent 18F-FDG-PET/CT for staging of
advanced HNSCC. Of these, 56 had induction chemotherapy as initial treatment; 31
of them were restaged after induction chemotherapy by a second 18F-FDG-PET/CT.
Twenty-five patients were not restaged by 18F-FDG-PET/CT for the following
reasons: died of disease (n=10), or restaged by other imaging modalities (CT n=9;
Magnetic Resonance Imaging (MRI) n=4). Furthermore, the treatment plan of one
patient was changed after two cycles to a palliative scheme with methotrexate
without an imaging technique for re-staging (n=1), and another patient needed to
stop the induction chemotherapy after one cycle due to an aggravated
thrombocythaemia (n=1).
In order to evaluate only pre-treatment-naïve patients, 10 out of the remaining 31
patients had to be excluded, since the actual treatment was a second-line therapy.
Finally, 21 patients meeting our final selection criteria could be included. The details
regarding tumor characteristics and the treatment scheme are shown in tables 1 and
2.
4.2. Induction chemotherapy
Out of the 21 included patients, 12 underwent the typical 'DCF' scheme consisting of
docetaxel, cisplatin and 5-fluorouracil. 2 patients initially treated with cisplatin needed
to be substituted by carboplatin due to hearing impairment or kidney dysfunction.
Another group (6 patients) was treated with the combination of cetuximab, 5-
fluorouracil and carboplatin or cisplatin. Only one patient received the combination of
carboplatin and 5-fluorouracil without cetuximab as this patient worried about the
possibility of skin problems. Details of chemotherapy schemes are shown in table 3.
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4.3. Pathology results
The results are shown in table 5. Most patients showed poorly differentiated tumor
cells. The MIB-1 score ranged from 10% to 80% with the majority of patients having a
score of 40% or higher. Both of these histological parameters indicated a rather
aggressive tumor. Most patients showed a GLUT score of 2 or 3 suggesting an
advanced malignancy of the tumor, whereas the regression score was rather low,
meaning that the majority of the tumor cells were vital.
4.4. Results of the 18F-FDG-PET/CT findings
The measured parameters SUVmax, tumor volume in cm³, bloodpool and threshold of
each patient are shown in table 4. The absolute SUV was calculated with the
equation SUVabs = SUVmax – SUVbloodpool. Table 5 presents the change of the SUVabs
between the staging 18F-FDG-PET/CT and the re-staging 18F-FDG-PET/CT as well
as the change of the tumor volume. The response to induction chemotherapy differed
notably from patient to patient. In certain cases (e.g. patient 12), SUV was reduced to
the level of SUVbloodpool, resulting in an almost complete disappearance of the tumor,
translating into a complete response. On the other hand, patient 1 revealed increased
tumor uptake but inversely reduced tumor volume. Some patients showed no change
at all after therapy. Overall, 6 patients were determined as non-responders, 7 as
partial responders and 8 as complete responders (table 6). In the section “Figures”
(chapter 8) the 18F-FDG-PET/CT findings of one patient are set out as an example of
a complete responder (Fig. 1) and of another patient who exhibited no SUV change
and an increase in the tumor volume as an example of a non-responder (Fig. 2).
After a mean follow-up of 12 months, 6 patients were dead of disease, of which 5 had
been classified as partial or non-responders and only 1 patient had been classified as
a complete responder by 18F-FDG-PET/CT.
4.5. Statistical results
No significant correlation (p=0.472) could be established between the response of
the patients and the histological grading. Further, there was no significant correlation
between the response of SUV and the composition of the chemotherapy (p=0.465).
No correlation between the response SUV and overall cycles (p=0.407) could be
14
shown, neither. Last but not least, there was no significant correlation between the
response of SUV and T-stage or location of the primary tumor (p=0.557 and p=0.054,
respectively). The latter comparison was able to show a statistical tendency towards
the response of SUV and tumors arising from the hypopharynx.
15
5. Discussion
In our study, we were unable to identify a significant correlation between
histopathological or therapeutic characteristics and the response, defined by 18F-
FDG-uptake reduction in 18F-FDG-PET/CT imaging as a surrogate for response.
However, reduction of 18F-FDG-uptake of 18F-FDG-PET/CT after induction
chemotherapy seems to be related to patient outcome since a pronounced number of
so called responders were still alive compared to non-responders.
The aim of our study was to find out, if histopathological parameters of the untreated
primary tumor in HNSCC e.g. initial primary tumor grade, proliferation index, glucose
transporter protein 1 (GLUT-1) expression could be possibly related to therapy
response. Even if one of the histopathological parameters of untreated tissue would
correlate to response or non-response, futile therapies could be omitted. This
decision pathway is actually known in specific anti-body treatment in other solid
tumors like bronchial carcinoma or colon cancer but not for HNSCC [20]. Since the
common histopathological evaluation does not include highly sophisticated, gene-
based analyses, a correlation was initially also not expected. Especially, in this study,
no significant correlation regarding 18F-FDG-PET/CT response to histological factors
like grade of differentiation, MIB-fraction or regression score could be found. Other
studies could demonstrate, that p53 [21] as well as class III beta-tubulin [22] could be
inversely correlated to progressive free survival and response rate to chemotherapy
regimens also used in this study. For this study, these known factors could not be
analyzed due to the retrospective nature of the data.
We defined the responders and non-responders by means of the SUV change in the
18F-FDG-PET/CT examinations because in general, reduction of 18F-FDG-uptake in
18F-FDG-PET and 18F-FDG-PET/CT imaging after any intervention in oncological as
well as inflammatory disease is regarded as response and possibly correlates with
disease outcome. The probably best studied disease regarding therapy response
assessment is lymphoma [23]. Here, reduction and normalization of 18F-FDG-uptake
in treated lymphoma has been significantly correlated to progression free survival
[24]. For solid tumors similar results could be demonstrated as for example in
esophageal cancer [25].
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The use of 18F-FDG-PET and 18F-FDG-PET/CT imaging in the evaluation of
HNSCC is well established, since squamous cell carcinoma also demonstrate a high
avidity in 18F-FDG-uptake and allows for the correct staging of this type of tumor [26,
27]. Regarding therapy evaluation after completion of radio-chemotherapy in a
curative intent, a high negative predictive value has been demonstrated [28].
Relatively few data has been published regarding the use of 18F-FDG-PET/CT in the
evaluation of therapy response assessment in advanced HNSCC treated by induction
chemotherapy, since this treatment is a relatively new approach in the curative
setting. In a study by Kikuchi et al., histopathological response as gold-standard was
compared to 18F-FDG-PET/CT- and MRI responses since all 16 included patients
were surgically treated after induction chemotherapy with available histological
specimens [13]. Using a threshold of 55.5% reduction in SUVmax, histopathological
response could be predicted with a sensitivity of 86% and specificity of 95%. These
results strongly underline not to say prove our working hypothesis that reduction in
SUV of more than 75% was correlated to histopathological response, since we had
no access to post-chemotherapy histology and the majority of our patients were
treated by non-surgical treatment. The problem of not having surgical specimens
available after induction chemotherapy is due to the concept of organ-preservation
therapy; therefore imaging modalities for monitoring therapy response after induction
chemotherapy seem to be a useful method. Having a look at our 18F-FDG-PET/CT-
related results for response, 8 patients showed a complete response (reduction of
SUVabs > 75%); 7 patients a partial response and 6 patients showed no response at
all. Therefore, less than 50% demonstrated a complete metabolic response.
In summary, we observed a large variation in the response to induction
chemotherapy; however, we could not identify a single factor which might explain that
difference. For example, there was no significant correlation (p=0.472) between
response and histological grading. Further, there was no significant difference
between the SUV response and the composition of the chemotherapy (p=0.465) as
well as the correlation to the overall number of chemotherapy cycles (p=0.407). No
significant correlation was identified between SUV response and T-stage (p=0.557)
nor between SUV response and location of primary tumor (p=0.054). As a certain
clinical surrogate for response, we used the clinical follow-up. The mean follow-up in
our patient population was 11.1 months which seems to be sufficiently long, since
17
early recurrence or persistence of disease occurs mostly within the first six months.
Interestingly, 6 patients died of disease, of whom 2 were classified as non-
responders, 3 as partial responders and 1 as a complete responder. Therefore,
response to induction chemotherapy before definite curative treatment shows a
positive effect on outcome, which is obviously the general purpose of this treatment.
Therefore, response to treatment can be determined in a non-invasive manner using
sequential 18F-FDG-PET/CT imaging. The translation of these findings into clinical
routine seems on the one hand straightforward, however, on the other hand, how
should patients be treated, who were re-staged as so called non- or partial
responders? Obviously one cannot conclude that further treatment should be
withdrawn, because the remaining 15 patients continued to survive, regardless of
their classification as complete, partial or non-responders.
A limitation of this study is the small patient population of 21 patients whom we
examined. In our limited sample instances of moderately differentiated tumor tissue
are underrepresented (7 out of 21 cases) compared to 14 instances of poorly
differentiated tumor. With a small number of patients it is difficult to derive statistically
significant values.
In conclusion, none of the histological parameters we examined (histological grading,
MIB score, GLUT-1 score, regression score), are able to serve as an indicator before
induction therapy as to whether a patient could likely benefit. However, the 18F-FDG-
PET/CT findings show a wide discrepancy in SUV response as well as the change of
the tumor volumes between patients. This is important information for making further
efforts to find a way to improve the criteria for determining which patients should be
treated by induction chemotherapy. A further search for certain tumor characteristics
which could have an influence on the outcome of induction chemotherapy will be an
important field for future research. For example, the examination of HNSCC which
are positive for human papillomavirus (HPV) may react differently than those which
are HPV negative. This could be of importance, since the proportion of HNSCC that
has been tested HPV positive has risen during the last few years.
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7. Tables
Table 1. Clinical characteristics of the 21 patients with induction chemotherapy as first line therapy
Women 2 9.5%
Men 19 90.5%
Age (years)
Mean 57.1
Range 42-75
Location of primary HNSCC
Oral cavity 2 9.5%
Oropharynx 5 23.8%
Hypopharynx 9 42.9%
Larynx 2 9.5%
Epipharynx 1 4.8%
Other 1 4.8%
Unknown 1 4.8%
Induction chemotherapy
T/C/F 12 57.1%
CB/F/E 3 14.3%
C/F/E 3 14.3%
T/CB/F 2 9.5%
CB/F 1 4.8%
The proportion refers to the total of 21 patients, Abbreviations: C: cisplatin CB: carboplatin
E: Erbitux ® (cetuximab), F: 5-fluorouracil, T: Taxotere ® (docetaxel)
Patient No. Gender Age Location of primary tumor TNM stage Histological grading First-line therapy Second-line therapies Follow-up (months) DOD
1 m 63 larynx T3 N3 M0 moderately differentiated cur-Ind RT/C, ND², C 12 no
2 m 52 hypopharynx T4b N2 Mx moderately differentiated cur-Ind RT/C 5 no
3º m 52 oral cavity T4 N0 Mx poorly differentiated cur-Ind 5 yes
4¹ m 53 hypopharynx T4 N0 M0 moderately differentiated cur-Ind 13 no
5 m 64 epipharynx T4 N0 Mx moderately differentiated cur-Ind 1 yes
6 m 64 oropharynx T4 N2 M0 poorly differentiated cur-Ind RT/C, salvage-ND 7 no
7 m 55 oropharynx T4 N2 M1 moderately differentiated cur-Ind RT/C, C 11 yes
8 m 75 larynx T4 N0 Mx poorly differentiated cur-Ind RT/C 5 yes
9 m 42 other T3 N2 Mx poorly differentiated cur-Ind 1 no
10 m 62 hypopharynx T4 N3 M1 moderately differentiated cur-Ind RT/C 21 no
11 m 55 unknown T0 N3 M1 poorly differentiated cur-Ind RT/C, ND 14 no
12 m 46 oropharynx T4 N2b M0 poorly differentiated cur-Ind RT/C 22 no
13 m 68 hypopharynx T4 N2 M0 moderately differentiated cur-Ind RT/C, Resection³ 9 no
14 m 47 hypopharynx T1 N3 M0 poorly differentiated cur-Ind RT/C, ND² 31 no
15 m 44 oral cavity T2 N0 M0 poorly differentiated Resection RT/C, cur-Ind 10 yes
16 m 48 hypopharynx T3 N3 M0 poorly differentiated cur-Ind RT/C, salvage-ND 14 no
17 m 54 hypopharynx T2 N2c M1 poorly differentiated cur-Ind C 9 no
18 m 52 hypopharynx T2 N2b M0 poorly differentiated cur-Ind RT/C, ND 32 no
19 f 68 unknown T0 N2b M1 poorly differentiated p-Ind C 7 yes
20 m 66 oropharynx T4b N2 M0 poorly differentiated cur-Ind RT/C 7 no
21 f 70 oropharynx T2 N0 M0 poorly differentiated cur-Ind C 17 no
Table 2. Details of 21 patients with induction chemotherapy followed by a re-staging with PET/CT
º:This patient had 8 years prior to current diagnosis surgery and RT because of another HNSCC
¹:This patient had 8 years prior to current diagnosis induction chemotherapy and RT/C because of another HNSCC
² : because of persisting lymph node Metastasis, ³ : transoral laser resection because of persisting primary tumor, Abbreviations: ND: neck dissection,
RT/C: concomittant radiochemotherapy, p-Ind: palliative induction chemotherapy, cur-Ind: curative induction chemotherapy, C: chemotherapy, DOD: dead of disease23
Patient No. Induction chemotherapy Overall cycles Re-staging PET/CT¹
1 CB/F/E 3 3
2 T/C/F 3 2
3 T/C/F 6 3
4 T/C/F 5 3
5 T/CB/F 3 3
6 T/CB/F 3 3
7 C/F/E 6 3
8 CB/F/E 3 3
9 T/C/F 3 2
10 T/C/F 3 3
11 T/C/F 3 3
12 T/C/F 4 4
13 T/C/F 4 4
14 T/C/F 3 3
15 C/F/E 6 3
16 T/C/F 3 3
17 CB/F 4 3
18 T/C/F 4 4
19 CB/F/E 3 3
20 T/C/F 3 2
21 C/F/E 4 3
Table 3. Details about the induction chemotherapy of all 21 patients with a PET/CT for re-staging
¹: This column shows after how many cycles the PET/CT was done for re-staging
Abbreviations: C: cisplatin, CB: carboplatin, E: Erbitux® (cetuximab), F: 5-fluorouracil, T: Taxotere® (docetaxel)
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Patient No. SUVmax PET/CT 1 Tumor volume PET/CT 1¹ Bloodpool PET/CT 1 Threshold PET/CT 1 SUVmax PET/CT 2 Tumor volume PET/CT 2¹ Bloodpool PET/CT 2 Threshold PET/CT 2
1 5.4 130 1.7 31 7.8 45 2.2 28
2 15.9 126 2.4 15 5.4 37 2.3 43
3 16.8 18 3 18 9.8 16 2.7 28
4 11.5 23 2.4 21 11.7 27 2.4 21
5 13.4 163 3.1 23 13.5 350 3.2 23
6 12.3 133 2.3 19 4.7 23 2.1 45
7 15.1 155 2.2 15 3.4 15 2.2 65
8 8.9 158 1.7 19 10.7 139 2.7 25
9 9 134 2.3 25 10.1 59 2.2 21
10 10.4 28 2.6 25 3.1 6 2.4 77
11 12.9 92 2 17 3.6 3 2.5 70
12 23.8 188 2.9 12 3 4 2.5 83
13 7.8 76 3 38 6 6 2.9 48
14 20.7 156 1.8 9 2.8 5 1.9 62
15 7.4 72 2.2 30 3.3 26 1.8 55
16 21.6 72 2.7 13 9.9 10 2.6 26
17 10.3 137 2.1 20 5.9 36 2.2 37
18 12.3 75 2.3 19 3.4 6 2.1 62
19 5.1 75 1.9 37 4.6 9 2.3 50
20 10.1 134 2.8 28 4 3 2.5 62
21 6.8 53 2.4 35 15.2 40 2.3 15
Table 4. SUVmax, tumor volume in cm3, bloodpool and threshold of the 21 patients with induction chemotherapy as first-line treatment
¹: Tumor volume includes the volume of the primary tumor plus the volume of the cervical lymph node metastasis, Abbreviations: PET/CT 1: PET/CT for staging, PET/CT 2: PET/CT for re-staging
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Patient No.
SUVabs change
between first and
second PET/CT
SUVabs change
in %²
Change of tumor volume in
cm³ between first and
second PET/CT¹
Change of tumor
volume in %² Histological grading MIB score GLUT-1 score
Tumor regression
score
1 1.9 51.4% -85 -65.4% moderately differentiated 40% 2 1
2 -10.4 -77.0% -89 -70.6% moderately differentiated 70% 3 1
3 -6.7 -48.6% -2 -11.1% poorly differentiated 20% 2 0
4 0.2 2.2% 4 17.4% moderately differentiated 70% 3 0
5 0 0.0% 187 114.7% moderately differentiated 40% 2 1
6 -7.4 -74.0% -110 -82.7% poorly differentiated 60% 1 1
7 -11.7 -90.7% -140 -90.3% moderately differentiated 40% 2 0
8 0.8 11.1% -19 -12.0% poorly differentiated n.m. n.m. n.m.
9 1.2 17.9% -75 -56.0% poorly differentiated 50% 1 n.m.
10 -7.1 -91.0% -22 -78.6% moderately differentiated 30% 2 1
11 -9.8 -89.9% -89 -96.7% poorly differentiated n.m. n.m. n.m.
12 -20.4 -97.6% -184 -97.9% poorly differentiated 50% 3 0
13 -1.7 -35.4% -70 -92.1% moderately differentiated 60% 3 0
14 -18 -95.2% -151 -96.8% poorly differentiated 70% 2 1
15 -3.7 -71.2% -46 -63.9% poorly differentiated 50% 1 2
16 -11.6 -61.4% -62 -86.1% poorly differentiated 60% 2 1
17 -4.5 -54.9% -101 -73.7% poorly differentiated n.m. n.m. n.m.
18 -8.7 -87.0% -69 -92.0% poorly differentiated 40% 3 0
19 -0.9 -28.1% -66 -88.0% poorly differentiated 10% 2 n.m.
20 -5.8 -79.5% -131 -97.8% poorly differentiated 80% 3 0
21 8.5 193.2% -13 -24.5% poorly differentiated 80% 3 0
Table 5. Tumor response in PET/CT and the pathological characteristics of the 21 patients with induction chemotherapy as first-line therapy
¹: Tumor volume includes the volume of the primary tumor plus the volume of the cervical lymph node metastasis, ² : First PET/CT measure data as output value
Abbreviations: SUVabs: absolute standardized uptake value, PET/CT: 18F-FDG positron emission tomography combined with computed tomography, n.m.: not
measurable
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Table 6. Number of responder, non-responder and partial responder
Number of patients:
Percentage of the
total 21 patients:
Complete responder: 8 38.1%
Non-responder: 6 28.6%
Partial responder: 7 33.3%
Total patients: 21 100.0%
Responder: a change of the SUV abs of over minus 75% of the initial value
Non-responder: a change of the SUVabs of less than minus 25% of the initial value
Partial responder: a change of the SUVabs of between minus 25% and minus 75% of the initial value
27
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8. Figures
(Fig. 1) 46-year-old patient with a poorly differentiated HNSCC of the oropharynx,
diagnosed one month before the pre-induction chemotherapy 18F-FDG-PET/CT.
Lower row from left to right: axial fused PET/CT, axial PET, and maximum intensity
projection (MIP) of PET data; primary tumor at the level of the oropharynx with
infiltration of the right parapharyngeal space. Upper row, left to right: axial PET/CT,
axial PET and MIP of PET after 4 cycles of induction chemotherapy with docetaxel,
cisplatin and 5-fluorouracil the post-induction chemotherapy 18F-FDG-PET/CT
shows a complete response (SUV of the tumor region is the same as the SUV of the
bloodpool).
Figure 1
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(Fig. 2) 64-year old patient with a poorly differentiated HNSCC of the maxillary of the
right side. Lower row from left to right: axial fused PET/CT, axial PET, and maximum
intensity projection (MIP) of PET data; primary tumor at the level of the right maxillary
ridge with infiltration of the soft and hard palate and bilateral lymph node metastases.
Upper row, left to right: axial PET/CT, axial PET and MIP of PET after 3 cycles of
induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil shows extensive
progression with infiltration of the right as well left parapharyngeal space.
Figure 2
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